Porton Advanced and T&L biotechnology Announce Strategic Partnership to Strengthen the Global CGT Supply Chain

SUZHOU, China (March 12, 2026) — Porton Advanced, a leading cell and gene therapy CDMO in China, today announced a strategic partnership with T&L biotechnology, a premier supplier of GMP-grade raw materials for the CGT industry. The collaboration aims to create a fully integrated supply chain solution—from critical raw materials to commercial manufacturing—helping CGT innovators accelerate drug development while reducing costs and risks.

Bridging the Gap Between Raw Materials and Commercial Manufacturing

As the CGT industry enters a pivotal phase of commercialization , securing a reliable, high-quality supply chain has become a top priority for drug developers. The partnership between Porton Advanced and T&L biotechnology directly addresses this challenge by combining upstream raw material expertise with downstream CDMO capabilities.

• A Seamless, End-to-End Solution: T&L biotechnology brings deep expertise in upstream critical GMP-grade raw materials, while Porton Advanced contributes significant capabilities in downstream process development and large-scale manufacturing. This partnership bridges the essential path from "raw material" to "final product," offering clients a more complete, consistent, and cost-effective supply chain solution.
• Accelerating Development Through Joint Innovation: By aligning early in the development process, Porton Advanced and T&L biotechnology will collaborate on process optimization and quality control, helping clients overcome common technical hurdles and shorten timelines to clinic and market.
• Reducing Risk, Increasing Certainty: The partnership provides clients with greater supply chain transparency and reliability. With both companies committed to quality and regulatory excellence, developers can mitigate risks associated with raw material variability and supply disruptions—two of the most critical challenges in CGT today.

Wang Liyan, Chairman and Founder of T&L biotechnology , stated: "Porton Advanced is a recognized leader in China's CGT CDMO sector, with an exceptional platform and a strong track record. We are delighted to establish this strategic partnership. It represents not only a powerful combination of resources but also a key step in our mission to provide holistic solutions to the CGT field. By leveraging our strengths in raw materials, we aim to help

Andrew Chen, CEO of Porton Advanced, commented: “ T&L biotechnology has built an impressive portfolio of raw materials that are critical to CGT development. By collaborating together, we can offer our clients a more resilient supply chain and a smoother path to commercialization. It's another step forward in our mission to make advanced therapies more accessible to patients around the world.”

About T&L biotechnology

T&L Biotechnology Ltd.,focuses on the research and development of upstream GMP grade raw materials and reagents for cell and gene therapy (CGT). We commit to providing total solution of products and services for CGT customers. Our products include cell separation & activation magnetic beads, eukaryotic/prokaryotic recombinant protein, serum-free medium, cell culture kits, etc.
We has a research and development laboratory and a GMP level clean workshop of 3200m², including cell separation magnetic beads development platform, eukaryotic and prokaryotic protein expression engineering platform, serum-free mediumdevelopment platform. We are in conformity with both ISO13485 and ISO9001 Quality Management System Standard. Some products have been FDA DMF filed.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 24 global IND approvals from NMPA, FDA, and Medsafe, with 11 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.

Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.